RP 66055

Drug Profile

RP 66055

Latest Information Update: 09 Dec 1996

Price : $50

At a glance

  • Originator Aventis
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Epilepsy; Neurological disorders

Most Recent Events

  • 09 Dec 1996 Discontinued-Preclinical for Neurological disorders in France (PO)
  • 08 Nov 1994 Discontinued-Preclinical for Epilepsy in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top